JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

25 апр 2024 08:30:48 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

21 мар 2024 16:01:27 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

18 мар 2024 08:30:30 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

15 мар 2024 08:30:01 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

13 мар 2024 08:30:14 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

05 янв 2024 08:30:12 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

02 янв 2024 16:05:30 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 дек 2023 08:00:51 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 ноя 2023 16:01:18 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 окт 2023 08:30:12 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 окт 2023 08:30:59 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 сен 2023 08:00:04 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 авг 2023 16:01:33 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 авг 2023 16:01:42 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 июл 2023 08:30:20 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 июл 2023 08:00:00 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 июн 2023 08:30:59 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 май 2023 16:01:31 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 май 2023 16:01:27 Источник Nasdaq GlobeNewswire